| 摘要 |
The present disclosure relates generally to compositions having a glucosidase inhibitor (castanospermine or a derivative thereof, such as celgosivir) in combination with adjunctive therapies of compounds that alter immune function (such as interferon) and compounds that alter viral replication (such as nucleoside analogues like ribavirin), which can be used to treat or prevent infections caused by or associated with a virus of the Flaviviridae family, particularly infections caused by or associated with Hepatitis C virus (HCV).
|
